DISAJP NEWS Vol.35 February 4th, 2021 – Dementia and diabetes named in the world’s ten leading killers

( ​​Dementia Improved Support Association of Japan )

This email is sent to those who subscribes DISA NEWS, the newsletter from the Dementia Improved Support Association of Japan.

We deliver the newsletter on the 4th of each month

to bring you valuable information, aiming to achieve the dementia-free world.

We offer sincere prayer for the repose of the souls of those who lost their lives with COVID-19 spreading across the world,

and our deepest sympathy to those infected.

We wish them quick recovery and hope that everyone in diffi​​culties get life back to normal soon.

We hope to contribute to avoiding the elderly people’s risk for death from the virus.

At the same time,

the organization continues helping people get peaceful days back by supporting cognitive function’s recovery.

We stay active on our mission.


​​Contents

〇 Dementia and diabetes named in the world’s ten leading killers

〇 World COVID-19 infection exceeded 104.14 million

〇 Coronavirus support for people affected by dementia

〇 Screening of Alzheimer’s disease by facial complexion using AI

〇 Rarer types of dementia

〇 Clinical trial being initiated for Japanese drug maker Eisai’s BAN2401

〇 Sea mail available for overseas delivery


〇 Dementia and diabetes named in the world’s ten leading killers

WHO released the top ten cause of death in 2019.
The killers accounted for 55% of the 55.4 million deaths worldwide during the year.

The top cause of death is ischaemic heart disease,

followed by stroke,

chronic obstructive pulmonary disease,

lower respiratory infections,

neonatal conditions,

trachea,

bronchus or lung cancers,

Alzheimer’s disease and other dementias,

diarrhoeal diseases,

diabetes mellitus,

and kidney diseases.

The top 10 causes of death

Dementia and diabetes named in the world’s ten leading killers

Who could have imagined this!?

Dementia and diabetes named in the world’s ten leading killers.

 


〇 World COVID-19 infection exceeded 104.14 million

The world nouvelle coronavirus infection has exceeded 104.14 million, with death toll reaching to 2.259 million.

According to Johns Hopkins University, world COVID-19 infection

and death toll reached 2,259,391 and 104.14 million respectively, as of 3 am on February 4 in Japan time.

https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6​

Dementia and diabetes Covid-19 map

Countries with the largest number of infections:

∇ The US (26,454,319)
∇ India (10,777,284)
∇ Brazil (9,283,418)
∇ The UK (3,882,972)
∇ Russia (3,858,367)

Countries with the largest fatalities:

∇​ ​The US (447,852)
∇​ ​Brazil (226,309)
∇ Mexico (159,533)
∇​ ​I​​ndia (154,596)
∇​ ​The UK (109,547)


​​〇 Coronavirus support for people affected by dementia

Showing no sign of ceasing, the number of the global COVID-19 infection has exceeded 100 million as of 14:30 on January 26 EST.

The number was doubled in less than 3 months, accelerated by expansion of the mutant strain with higher infectability.

Spanish flu, epidemic a century ago, is estimated to have had 500 million infections.

675 thousand people were killed only in the United States, among the world estimated death toll 50 million or more.

As of January 6 in 2021, seven countries haven’t had any case of infection.

1. Samoa (0 case, except for the one with a sailor infected abroad)
2. Kiribati
3. Micronesia
4. Tonga
5. Palau
6. Tuvalu
7. Nauru

Although being resort destinations, these countries usually have relatively fewer tourists.

Each country is an island state with small population,

where lock down or travel restriction was ordered in the very early stage.

With these limited exceptional countries the world is overwhelmed by the virus,

but even in such a difficult time there are some support available for those who are living with somebody with dementia.

The stress of the pandemic should make it harder to cope with distress of your loved one’s disease,

so hopefully you can reach any necessary service.

If you need help living with or supporting somebody with dementia during the coronavirus pandemic,

we’re here for you.

You may feel anxious, scared or lonely.

But you are not alone – help is available.

https://www.alzheimers.org.uk/get-support/coronavirus


​​〇 Screening of Alzheimer’s disease by facial complexion using AI

The following link is the report of a study aimed to examine

whether AI can distinguish facial traits of cognitive impairment patients from that of non-dementia patients.

The findings of this study lay the foundations for the development of a non-invasive,

inexpensive and rapid screening tool for cognitive impairment using AI.

https://www.aging-us.com/article/202545/text


〇 Rarer types of dementia

Apart from the Alzheimer’s, the most common type of dementia,

there are a number of rarer diseases and symptoms potentially leading to dementia and similar dysfunctions,

or mild cognitive impairment.

In the UK, one in every 20 has a rarer type of dementia as below.

Atypical Alzheimer’s disease

— Frontal variant Alzheimer’s disease  (fvAD)

— Posterior cortical atrophy (PCA)

CADASIL

Corticobasal syndrome (CBS)

Creutzfeldt–Jakob disease (CJD)

HIV-associated neurocognitive disorder (HAND)

Huntington’s disease

Normal pressure hydrocephalus (NPH)

Progressive supranuclear palsy (PSP)

Rarer types of dementia may also be caused by something different,

such as an infection that affects the brain. Others, such as CADASIL and Huntingdon’s disease, are caused by a person having a faulty gene.

It is not fully understood why a person might develop a rarer type of dementia rather than a common type.

https://www.alzheimers.org.uk/about-dementia/types-dementia/rarer-types-dementia


〇 Clinical trial being initiated for Japanese drug maker Eisai’s BAN2401

A Japanese major pharmaceutical company Eisai will initiate international joint clinical trials for BAN2401,

a dementia preventive medicine, aiming to complete the development.

The trials will be conducted for those with normal cognitive functions,

namely males and females at the age of 55 to 80 having amyloid beta accumulation without showing any symptoms.

The program will be headed by the Alzheimer’s Clinical Trials Consortium founded by the US National Institute of Health,

and implemented in the US, Japan, Canada, Australia, Singapore and the EU.

1,400 trialists from the world will be dosed for 4 years to test the effectiveness.

Alzheimer’s disease is known to be caused by brain cell damage induced by accumulation of a protein called amyloid beta,

which begins 10 to 20 years before the onset.

BAN2401 is expected to have an efficacy to avoid amyloid beta in the brain.

In the 4 year program, some factors such as amyloid beta accumulation

and changes in cognitive functions will be compared,

dosing the medicine once 2 to 4 weeks to a certain trialists and placebo to the rest.

Ahead of the international phase, the US has already started the administration in September 2020.

In Japan, dozens of people are planned to participate.

Although similar trials have been conducted aiming to develop amyloid beta removing drugs, none of them was successful.

After analyzing those trials and concluding

that dosing after the development of the symptoms is unsuccessful as the patients’ brains are already damaged,

Eisai’s researchers designed the program to target those who haven’t had the onset.

Unfortunately, BAN2401 won’t be effective for those after the onset, and also for the patients of early onset Alzheimer’s

The medicine certainly has potential to be a preventive option,

but many elements are to be cleared, such as when to start the administration.


​​〇 ​​Sea mail available for overseas delivery

​​Our product KOUKA, a supplement patented as composition of matter to ameliorate cognitive dysfunctions,

has been enormously well-received by many users around the world.

However, overseas delivery has been difficult due to COVID-19.

Please be advised that all the overseas deliveries are conducted via sea mail until the pandemic goes down.

Sea mail covers many countries, although it takes longer (approximately 2-3 months).

The total cost for a package will be 41,000JPY

including the product’s price of 39,000JPY and uniform sea mail charge of 2,000JPY.

 

To place an order, please let us know your details as below via the inquiry form for overseas customers.

Sea mail available for overseas delivery

1. Name
2. Address
3. Phone number
4. Email address
5. Recipient’s age, current status and other details that should be informed
6. Number of order (a package weighs about 600g)

Sea mail available for overseas delivery

​​We will charge the total amount including the product’s price (39,000JPY) and sea mail charge (2,000JPY) via PayPal.

The item will be dispatched upon confirmation of the payment.

Please note that customers need to check on the custom duty for your country before ordering.

Don’t forget to make sure if you can receive the item in your area,

as some countries prohibit the import of supplements.


Thank you very much for your understanding and support to our activities.

We greatly appreciate medical professionals in the world for their dedicated work against the treats of COVID19.

Our association aims to bring more smiles in families, by supporting cognitive function’s recovery.

For the recovery, normalizing microcirculation is highly efficacious.

We found dosing proper amount of reishi, a gift of nature, is essential for better microcirculation.

KOUKA is a processed food product of Ganoderma Lucidum (reishi),

patented in Japan as a composition of matter to ameliorate cognitive dysfunctions.

Almost 100% of KOUKA users who took it for 3 months experienced alleviation of cognitive dysfunctions and life style diseases.

We strongly believe cognitive functions can be recovered

and there is no need to give up even after the onset of dementia.

With this conviction, our association has conducted physiological studies for more understanding of the nature of human body,

as well as offering a wide range of awareness campaigns.

We are always open to share what we found with many people as possible.


We strongly believe cognitive functions can be recovered and there is no need to give up even after the onset of dementia.

With this conviction, our association has conducted physiological studies

for more understanding of the nature of human body,

as well as offering a wide range of awareness campaigns.

We are always open to share what we found with many people as possible.


​How was the content of this e-mail magazine “Dementia and diabetes named in the world’s ten leading killers” ?

We deliver further information at the official website.

https://disajp.org/

DISAJP distributes valuable information on the 4th of each month to the world.

We welcome your feedback.

You can purchase the high quality reishi supplement KOUKA efficacious for improving cognitive functions at DIS SHOP.

https://dis-shop.info/

©2022 一般社団法人認知機能改善サポート日本協会

ユーザー名とパスワードでログイン

ログイン情報を忘れましたか?